Bavisant dihydrochloride hydrate (JNJ31001074AAC) 是口服活性人H3 受体拮抗剂。
| 生物活性 |
Bavisant dihydrochloride hydrate (JNJ31001074AAC) is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD. IC50 Value: Target: H3 receptor in vitro: Bavisant completed a phase II ADHD trial, but no results have been reported [1]. in vivo: Mean change from baseline in the total ADHD-RS-IV score at day 42 (primary efficacy endpoint) was -8.8 in the placebo group versus -9.3, -11.2 and -12.2 in the bavisant 1 mg/day, 3 mg/day and 10 mg/day groups, respectively; the change in the 10 mg/day group was not statistically superior to placebo (p=0.161), and hence statistical comparisons of the 1 mg/day and 3 mg/day groups with placebo based on a step-down closed testing procedure were not performed [2]. Clinical trial: A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. Phase 2 |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 分子式 |
C19H31Cl2N3O3
|
||||||||||||||||
| 分子量 |
420.37
|
||||||||||||||||
| CAS号 |
1103522-80-0
|
||||||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
| 储存方式 |
|
||||||||||||||||
| 溶解性数据 |
In Vitro:
H2O : ≥ 50 mg/mL (118.94 mM) DMSO : ≥ 1 mg/mL (2.38 mM) * "≥" means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
|
||||||||||||||||
| 临床试验 |
|
纯度： 98%
客服小K 
客服小K
Data Sheet
